Interlaboratory Comparison of Short-Term Carcinogenicity Studies Using CB6F1-rasH2 Transgenic Mice

Abstract

In order to evaluate a short-term carcinogenicity testing system using CB6F1-Tg rasH2 ( rasH2-Tg) mice carrying a human prototype c-Ha-ras gene, 26-week studies were conducted in 12 different facilities as a part of an International Life Science Institute Health and Environmental Science Institute (ILSI HESI) international collaborative project. In each study N-methyl-N-nitrosourea (MNU) was administered to a separate group of rasH2-Tg mice by single intraperitoneal injection (75 mg/kg) as a positive control. We herein have summarized the mortality, body weight change, and neoplastic and nonneoplastic lesions detected in these positive control groups as representative historical positive control data. Also, we performed an interlaboratory comparison of the response of rasH2-Tg mice to MNU based on the data of 11 positive control groups from these studies. Although the body weight of rasH2-Tg mice showed lower values than that of non-Tg mice during the experimental period, body weight gain in the rasH2-Tg mice was similar to that in non-Tg mice. The mortality of rasH2-Tg mice during the study period was very low, the same as for the non-Tg mice. Incidences of spontaneous alveolar/bronchiolar adenomas and splenic hemangiomas/hemangiosarcomas were also low in the rasH2-Tg mice. Nonneoplastic lesions detected in the rasH2-Tg mice were similar to those in non-Tg mice, excluding the incidence of myopathy. There were interlaboratory differences in mortality and incidence of some lesions in the MNU-treated groups. However, the causes of death were common among the 11 laboratories and almost all the MNU-treated rasH2-Tg mice developed forestomach squamous cell papillomas/carcinomas or malignant lymphomas. This suggests that there is no appreciable difference in the response of the rasH2-Tg mouse to MNU used as a positive control. Therefore, it is concluded that MNU would be an adequate positive control compound in this testing system.

Keywords

rasH2-Tg mouse human prototype c-Ha-ras gene short-term carcinogenicity testing ILSI HESI international collaborative project N-methyl-N-nitrosourea.

References

Boorman GA , Maronpot RR , Eustis SL (1994). Rodent carcinogenicity bioassay: Past, present, future. Toxicol Pathol 22: 105—111.

Butterworth BE , Conolly RB , Morgan KT (1995). A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments . Cancer Lett 93: 129—146.

Davies TS , Monro A. (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J Am Coll Toxicol 14: 90—107.

Gulezian D. , Jacobson-Kram D. , McCullough CB , Olson H. , Recio L. , Robinson D. , Storer R. , Tennant R. , Ward JM , Neumann DA (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol 28: 482— 499.

International Agency for Research on Cancer ( 1978). N-Nitroso-N-methylurea. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 17, Some N-Nitroso Compounds. International Agency for Research on Cancer, Lyon, France, pp 227— 255.

International Conference on Harmonization (1998). Guidance on testing for carcinogenicity of pharmaceuticals. Fed Regist 63: 8983—8986.

Katsutani N. , Sekido T. , Aoki T. , Sagami F. (2000). Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice. Toxicology Lett 115: 223— 229.

Maronpot RR , Mitsumori K. , Mann P. , Takaoka M. , Yamamoto S. , Usui T. , Okamiya H. , Nishikawa S. , Nomura T. (2000). Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology 146: 149—159.

Maruyama C. , Tomisawa M. , Wakana S. , Yamazaki H. , Kijima H. , Suemizu H. , Ohnishi Y. , Urano K. , Hioki K. , Usui T. , Nakamura M. , Tsuchida T. , Mitsumori K. , Nomura T. , Tamaoki N. , Ueyama Y. (2001). Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Rep 8: 233—237.

10.

Mitsumori K. , Koizumi H. , Nomura T. , Yamamoto S. (1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol 26: 520—531.

11.

Ohnishi Y. , Arai T. , Koshirakawa M. , Horii N. , Nakajo S. , Urano K. , Usui T. , Tamaoki N. , Ueyama Y. (2001). Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates. Exp Anim 50: 33—39.

12.

RobinsonDE , MacDonaldJS ( 2001).BackgroundandframeworkforILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicol Pathol 29 (Suppl): 13—19.

13.

Saitoh A. , Kimura M. , Takahashi R. , Yokoyama M. , Nomura T. , Izawa M. , Sekiya T. , Nishimura S. , Katsuki M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195—1200.

14.

Tamaoki N. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29 (Suppl): 81— 89.

15.

Tennant RW , French JE , Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103: 942— 950.

16.

Terracini B. , Testa MC (1970). Carcinogenicity of a single administration of N-nitrosomethylurea: A comparison between new-born and 5-week-old mice and rats. Br J Cancer 24: 588—598.

17.

Usui T. , Mutai M. , Hisada S. , Takaoka M. , Soper KA , McCullough B. , Alden C. (2001). CB6F1-rasH2 mouse: Overview of available data . Toxicol Pathol 29 (Suppl): 90—108.

18.

Ward JM , Shibata M. , Devor DE (1996). Emerging issues in mouse liver carcinogenesis . Toxicol Pathol 24: 129—137.

19.

Yamamoto S. , Hayashi Y. , Mitsumori K. , Nomura T. (1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS Gene . Lab Anim Sci 47: 121—126.

20.

Yamamoto S. , Mitsumori K. , Kodama Y. , Matsunuma N. , Manabe S. , Okamiya H. , Suzuki H. , Fukuda T. , Sakamaki Y. , Sunaga M. , Nomura G. , Hioki K. , Wakana S. , Nomura T. , Hayashi Y. (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17: 2455—2461.